MARKET

AGIO

AGIO

Agios Pharmaceuticals Inc
NASDAQ
22.90
+0.67
+3.01%
After Hours: 22.90 0 0.00% 16:20 12/01 EST
OPEN
22.14
PREV CLOSE
22.23
HIGH
22.93
LOW
21.53
VOLUME
344.85K
TURNOVER
0
52 WEEK HIGH
31.87
52 WEEK LOW
19.80
MARKET CAP
1.28B
P/E (TTM)
-5.8048
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at AGIO last week (1120-1124)?
Weekly Report · 11/27 09:03
Leerink Partners Sticks to Its Buy Rating for Agios Pharma (AGIO)
TipRanks · 11/22 11:58
Agios (AGIO) Meets Clinical Proof-of-Concept in Anemia Treatment
NASDAQ · 11/21 15:56
Promising Phase 2a Results and Strategic Moves Bolster Buy Rating for Agios Pharma: An Analysis of Harrison’s Recommendation
TipRanks · 11/21 00:55
Weekly Report: what happened at AGIO last week (1113-1117)?
Weekly Report · 11/20 09:03
Weekly Report: what happened at AGIO last week (1106-1110)?
Weekly Report · 11/13 09:03
Agios Pharmaceuticals Inc: Statement of acquisition of beneficial ownership by individuals
Press release · 11/09 22:23
Agios Pharmaceuticals Inc: [Amend]Statement of acquisition of beneficial ownership by individuals
Press release · 11/09 20:25
More
About AGIO
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of a- and b-thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The Company is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD and anemia associated with low-to intermediate-risk myelodysplastic syndrome (LR MDS), and hemolytic anemias.

Webull offers Agios Pharmaceuticals Inc stock information, including NASDAQ: AGIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AGIO stock methods without spending real money on the virtual paper trading platform.